Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non–Small-Cell Lung Cancer or Other Tumors

INTRODUCTION: Anaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer (NSCLC) is sensitive to ALK inhibitors, but resistance develops. This study assessed the maximum-tolerated dose, safety, pharmacokinetics (PK), and antitumor activity of ceritinib, a novel ALK inhibitor (ALKi), in J...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishio, Makoto, Murakami, Haruyasu, Horiike, Atsushi, Takahashi, Toshiaki, Hirai, Fumihiko, Suenaga, Naoko, Tajima, Takeshi, Tokushige, Kota, Ishii, Masami, Boral, Anthony, Robson, Matthew, Seto, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467585/
https://www.ncbi.nlm.nih.gov/pubmed/26020125
http://dx.doi.org/10.1097/JTO.0000000000000566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467585/
https://www.ncbi.nlm.nih.gov/pubmed/26020125
http://dx.doi.org/10.1097/JTO.0000000000000566

Ejemplares similares